Table 1 Characteristics of the studies included in the meta-analysis
Publication author, year | Country | Jadad score | Treatment arm A | Treatment arm B | Time of therapy | Sample size | Outcomes | Assessment method/Unit of primary outcome |
|---|---|---|---|---|---|---|---|---|
Seyam 2018 [19] | Egypt | 5 | Simvastatin(20 mg/d) +Metformin(1.5 g/d) | Metformin(1.5 g/d) | 12 months | 70/65 | T,DHEA, Hirsutism | ELISA assay/ ng/ml |
Seyam 2017 [24] | Egypt | 4 | Simvastatin(20 mg/d) | Placebo | 6 months | 100/100 | T,DHEA, Hirsutism,Acne | chemiluminescence assays/ ng/ml |
Puurunen 2013 [26] | Finland | 5 | Atorvastatin 20 mg/d | Placebo | 6 months | 15/13 | T,DHEA, And | Liquid mass spectrometry/ nmol/l |
Sathyapalan 2009 [22] | United Kingdom | 5 | Atorvastatin 20 mg/d | Placebo | 3 months | 19/18 | T | Immunoassay/ nmol/l |
Banaszewska 2011 [27] | Poland | 3 | Simvastatin(20 mg/d) +Metformin(1.7 g/d) | Metformin(1.7 g/d) | 6 months | 36/33 | T,DHEA, Hirsutism,Acne | enzymatic colorimetric assays/ ng/ml |
Raja 2011 [25] | American | 4 | Atorvastatin(40 mg/d) | placebo | 1.5 months | 9/11 | T,DHEA,And Hirsutism,Acne | not report/ ng/dl |
Rashidi 2011 [20] | Iran | 5 | Simvastatin(20 mg/d) | placebo | 2 months | 32/29 | T,DHEAS | chemiluminescence assays/ pg/ml |
Kazerooni 2010 [21] | Iran | 5 | Simvastatin(20 mg/d) +Metformin(1.5 g/d) | Metformin(1.5 g/d) | 3 months | 42/42 | T,DHEA,Hirsutism | Radioimmunoassay/ ng/ml |
Duleba 2005 [23] | Poland | 2 | simvastatin, 20 mg +OCP | OCP | 3 month | 24/24 | T,DHEA | chemiluminescence assays/ ng/dl |